STOCK TITAN

Aurora Cannabis Announces Collaboration on Genome BC-Funded Project Addressing Distinct Cannabis Aromas

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced a research collaboration with the University of British Columbia (UBC), funded by Genome British Columbia. The project, titled 'Genomics-enabled Aroma Breeding in Cannabis,' aims to validate genetic and chemical markers for fruity aroma in cannabis, a key consumer preference trait.

Led by Dr. Jose Celedon from Aurora and Professor Joerg Bohlmann from UBC, this research aligns with Aurora's breeding goals and will enhance its breeding program's accuracy and efficiency. The project will utilize Aurora's advanced cannabis genetic library and recent patents on fruity aroma markers. Aurora will contribute through sensory analysis and bioinformatic analyses, while UBC will focus on sequencing transcriptomes, analyzing volatile chemistry, and characterizing genes responsible for fruity aromas.

This collaboration demonstrates Aurora's commitment to innovation and scientific advancement in the cannabis sector, potentially impacting future product development and consumer satisfaction.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ha annunciato una collaborazione di ricerca con l'Università della Columbia Britannica (UBC), finanziata da Genome British Columbia. Il progetto, intitolato 'Selezione Aromatica Abilitata dalla Genomica nella Cannabis,' mira a validare marcatori genetici e chimici per l'aroma fruttato nella cannabis, una caratteristica di preferenza chiave per i consumatori.

Guidato dal Dr. Jose Celedon di Aurora e dal Professor Joerg Bohlmann dell'UBC, questo progetto di ricerca si allinea con gli obiettivi di allevamento di Aurora e migliorerà l'accuratezza e l'efficienza del suo programma di allevamento. Il progetto utilizzerà la biblioteca genetica avanzata di cannabis di Aurora e brevetti recenti sui marcatori di aroma fruttato. Aurora contribuirà attraverso l'analisi sensoriale e analisi bioinformatiche, mentre l'UBC si concentrerà sul sequenziamento dei trascrittomi, l'analisi della chimica volatile e la caratterizzazione dei geni responsabili degli aromi fruttati.

Questa collaborazione dimostra l'impegno di Aurora per l'innovazione e il progresso scientifico nel settore della cannabis, con il potenziale di influenzare lo sviluppo futuro dei prodotti e la soddisfazione dei consumatori.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ha anunciado una colaboración de investigación con la Universidad de Columbia Británica (UBC), financiada por Genome British Columbia. El proyecto, titulado 'Cría Aromática Habilitada por Genómica en Cannabis', tiene como objetivo validar marcadores genéticos y químicos para el aroma afrutado en cannabis, una característica clave de preferencia del consumidor.

Dirigido por el Dr. Jose Celedon de Aurora y el Profesor Joerg Bohlmann de UBC, esta investigación se alinea con los objetivos de cría de Aurora y mejorará la precisión y eficiencia de su programa de cría. El proyecto utilizará la biblioteca genética avanzada de cannabis de Aurora y patentes recientes sobre marcadores de aroma afrutado. Aurora contribuirá mediante análisis sensorial y análisis bioinformáticos, mientras que UBC se centrará en el secuenciamiento de transcriptomas, análisis de química volátil y caracterización de genes responsables de los aromas afrutados.

Esta colaboración demuestra el compromiso de Aurora con la innovación y el avance científico en el sector del cannabis, con el potencial de impactar el desarrollo futuro de productos y la satisfacción del consumidor.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB)는 유전자원 British Columbia 대학(UBC)과 연구 협력을 발표했습니다. 이 프로젝트는 '대마초의 유전자 기반 향기 품종 육성'이라는 제목으로 과일 향기의 유전자 및 화학 마커를 검증하는 것을 목표로 하고 있습니다. 이는 소비자 선호의 중요한 특성입니다.

Aurora의 Jose Celedon 박사와 UBC의 Joerg Bohlmann 교수의 주도로 진행되는 이 연구는 Aurora의 육종 목표에 부합하며 육종 프로그램의 정확성과 효율성을 향상시킬 것입니다. 이 프로젝트는 Aurora의 고급 대마초 유전자 라이브러리와 과일 향 마커에 대한 최근 특허를 활용할 것입니다. Aurora는 감각 분석과 생물정보학적 분석을 통해 기여하고, UBC는 전사체의 염기서열 분석, 휘발성 화학 분석, 과일 향기를 책임지는 유전자 특성 분석에 초점을 맞출 것입니다.

이 협력은 대마초 분야에서 혁신과 과학적 발전에 대한 Aurora의 의지를 보여주며, 향후 제품 개발과 소비자 만족에 영향을 미칠 수 있는 잠재력을 가지고 있습니다.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) a annoncé une collaboration de recherche avec l'Université de la Colombie-Britannique (UBC), financée par Genome British Columbia. Le projet, intitulé 'Sélection aromatique habilitée par la génomique dans le cannabis,' vise à valider les marqueurs génétiques et chimiques pour l'arôme fruité dans le cannabis, une caractéristique clé de préférence pour les consommateurs.

Dirigé par le Dr. Jose Celedon d'Aurora et le professeur Joerg Bohlmann de l'UBC, cette recherche est alignée avec les objectifs de reproduction d'Aurora et améliorera la précision et l'efficacité de son programme de reproduction. Le projet utilisera la bibliothèque génétique avancée de cannabis d'Aurora et des brevets récents sur les marqueurs d'arôme fruité. Aurora contribuera par le biais d'analyses sensorielles et d'analyses bioinformatiques, tandis que l'UBC se concentrera sur le séquençage des transcriptomes, l'analyse de la chimie volatile et la caractérisation des gènes responsables des arômes fruités.

Cette collaboration démontre l'engagement d'Aurora envers l'innovation et l'avancement scientifique dans le secteur du cannabis, ce qui pourrait avoir un impact sur le développement futur des produits et la satisfaction des consommateurs.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) hat eine Forschungskollaboration mit der Universität von British Columbia (UBC) angekündigt, die von Genome British Columbia finanziert wird. Das Projekt mit dem Titel 'Genomik-gestützte Aroma-Zucht in Cannabis' hat das Ziel, genetische und chemische Marker für fruchtiges Aroma zu validieren, eine zentrale Vorliebe der Verbraucher.

Unter der Leitung von Dr. Jose Celedon von Aurora und Professor Joerg Bohlmann von UBC steht diese Forschung im Einklang mit Auroras Zuchtzielen und wird die Genauigkeit und Effizienz des Zuchtprogramms verbessern. Das Projekt wird Auroras fortschrittliche genetische Bibliothek für Cannabis und aktuelle Patente zu fruchtigen Aromamarkern nutzen. Aurora wird durch sensorische Analysen und bioinformatische Analysen beitragen, während sich UBC auf das Sequenzieren von Transkriptomen, die Analyse flüchtiger Chemie und die Charakterisierung von Genen, die für fruchtige Aromen verantwortlich sind, konzentrieren wird.

Diese Zusammenarbeit zeigt Auroras Engagement für Innovation und wissenschaftlichen Fortschritt im Cannabissektor, was potenziell zukünftige Produktentwicklungen und die Zufriedenheit der Verbraucher beeinflussen könnte.

Positive
  • Collaboration with UBC on genome research, funded by Genome BC, reducing financial constraints for Aurora
  • Potential to enhance breeding program accuracy and efficiency for consumer-focused traits
  • Validation of recently patented genetic and chemical markers for fruity aroma
  • Possible strengthening of Aurora's aroma-related intellectual property portfolio
Negative
  • None.

Insights

This collaboration between Aurora Cannabis, UBC and Genome BC represents a significant step in cannabis genetics research. The focus on fruity aroma traits is particularly interesting, as it addresses a key factor in consumer preference. By validating genetic and chemical markers for these aromas, Aurora is positioning itself to enhance its breeding program with greater precision.

The potential outcomes of this research are promising:

  • Improved ability to develop cultivars with specific aroma profiles
  • Enhanced breeding efficiency for traits like yield, potency and disease resistance
  • Strengthening of Aurora's intellectual property portfolio in aroma-related genetics

While this research may not have an immediate financial impact, it could lead to long-term competitive advantages in product development and market share. The collaboration also demonstrates Aurora's commitment to scientific advancement in the cannabis sector, which may attract investor interest in the company's long-term growth potential.

NASDAQ | TSX: ACB

Research Project designed to validate breeding genetics connected with fruity aroma, a key patient and consumer preference trait, with positive impact on future innovation 

EDMONTON, AB, Oct. 2, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) –—the Canadian based leading global medical cannabis company, today announced a research grant provided to the University of British Columbia (UBC) by Genome British Columbia (Genome BC), a not-for-profit organization supporting world-class genomics research and innovation in British Columbia. The project, Genomics-enabled Aroma Breeding in Cannabis, will directly support Aurora's genetics work the project, is led by Drs. Jose Celedon, Principal Scientist, Breeding and Genetics at Aurora, and by Joerg Bohlmann, a professor at UBC, and is focused on validating genetic and chemical markers for fruity aroma in cannabis. This meaningful genetics research aligns with Aurora's breeding goals and will enable the company to enhance its breeding program with greater accuracy and efficiency on consumer-focused traits, positively impacting future innovation.

"Through this work Aurora will deepen our understanding of cannabis genetics with a focus on aromas, a leading driver of consumer preference that directly impacts the user experience," said Dr. Jose Celedon, Director, Breeding and Genetics at Aurora. "By collaborating with UBC on this Genome BC-funded project, we are able to fully execute this aroma research without the typical financial constraints, allowing us to continue simultaneous work on additional important breeding traits, such as yield, potency and disease resistance. We are eager to see the outcomes of our work and the impact on the future of cannabis breeding."

Aroma is a distinct characteristic of cannabis and an important aspect of consumer inclination. As a leader with one of the most advanced cannabis genetic libraries globally, Aurora will move beyond sensory analysis and into validated aroma markers with this research. Recently, Aurora patented a series of genetic and chemical markers for fruity aroma, identified through its CanD diversity panel. This collaboration will allow Aurora to validate these markers using cutting-edge approaches that would otherwise require significant funding. The data generated from this work will support the discovery and launch of cultivars with unique and improved aromas, alongside high yield and potency.

Aurora's in-kind contributions to the project include conducting sensory analysis of fruity aromas, and leading bioinformatic analyses with in-house software. UBC's contributions to the project through Genome BC funding, will involve sequencing transcriptomes, analysing the volatile chemistry, and conducting functional characterization of the genes responsible for fruity aromas in cannabis. If successful, the methods developed in this project will be adapted to explore other aromas and could further strengthen Aurora's aroma-related intellectual property portfolio.

This collaboration with UBC underscores Aurora's commitment to innovation and scientific advancement in the cannabis sector.  Aurora continues to push the boundaries of cannabis research and development, setting new standards for product quality and consumer satisfaction.

About Aurora Cannabis 

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn

About Genome British Columbia

Genome BC is a not-for-profit organization that has advanced genomics research and innovation for nearly 25 years, growing a world-class life sciences sector in BC and delivering sustainable benefits for British Columbia, Canada and beyond. Genome BC has attracted over $1 billion in direct co-investment to the province, which has contributed to funding more than 550 genomics research and innovation projects. These initiatives enhance healthcare and address environmental and natural resource challenges, improving the lives of British Columbians. Genome BC also integrates genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences among educators, students and the public. www.genomebc.ca 

Aurora's Common Shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding Aurora's research funding from Genome BC and associated benefits, including as related to the Company's breeding program, intellectual property and future innovation, as well as statements regarding the Company's continued commitment to innovation and scientific advancement in the cannabis sector.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-collaboration-on-genome-bc-funded-project-addressing-distinct-cannabis-aromas-302265216.html

SOURCE Aurora Cannabis Inc.

FAQ

What is the focus of Aurora Cannabis's new research project with UBC?

The research project, titled 'Genomics-enabled Aroma Breeding in Cannabis,' focuses on validating genetic and chemical markers for fruity aroma in cannabis, which is a key consumer preference trait.

How will the Genome BC-funded project benefit Aurora Cannabis (ACB)?

The project will allow Aurora to enhance its breeding program with greater accuracy and efficiency on consumer-focused traits, potentially leading to improved product innovation without typical financial constraints.

What contributions will Aurora Cannabis (ACB) make to the research project?

Aurora will conduct sensory analysis of fruity aromas and lead bioinformatic analyses using in-house software. They will also utilize their advanced cannabis genetic library and recent patents on fruity aroma markers.

How might this research impact Aurora Cannabis's (ACB) future products?

The research could lead to the discovery and launch of cannabis cultivars with unique and improved aromas, alongside high yield and potency, potentially improving product quality and consumer satisfaction.

Aurora Cannabis Inc. Common Shares

NASDAQ:ACB

ACB Rankings

ACB Latest News

ACB Stock Data

232.68M
54.75M
13.08%
5.13%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton